Skip to main content

Table 3 Diabetes management in urban and remote Indigenous Australians and remote Indigenous Canadians

From: Cardiovascular disease risk profile and microvascular complications of diabetes: comparison of Indigenous cohorts with diabetes in Australia and Canada

  Group 1: Remote Australian (n = 37) Group 2: Urban
Australian (n = 94)
Group 3: Remote Canadian (n = 188)
Diet/nil glucose-lowering medications 11 (30%) 9 (10%) 78 (41%)
Metformin 24 (65%) 52 (57%) 83 (44%)
Sulphonylurea 11 (30%) 32 (35%) 62 (33%)
Acarbose 0 2 (2%) 1 (0.5%)
Thiazolidinedione 0 6 (7%) 5 (3%)
Insulin 0 18 (19%) 34 (18%)
Aspirin* 16 (43%) 39 (43%) 36 (32%)
HMG CoA reductase inhibitor* 9 (24%) 35 (37%) 23 (20%)‡
ACE inhibitor or A2RA* 23 (62%) 59 (63%) 73 (64%)
  1. Data are n (%).
  2. p < 0.0001 when compared to Group 1
  3. ‡ p < 0.05 compared to Group 2
  4. *n = 114 for Remote Canadian group
  5. HMG CoA, 3-hydroxy-3-methylglutaryl-CoA; ACE, angiotensin converting enzyme; A2RA, angiotensin-2 receptor antagonist.